Up to 65 sick with 25 hospitalized.

We are representing 37 people sickened in the Carbón Live Fire Mexican Grill E. col Outbreak and Lawsuit.

What is E. coli?

E. coli O157:H7 was identified for the first time at the CDC in 1975, but it was not until seven years later, in 1982, that E. coli O157:H7 was conclusively determined to be a cause of enteric disease. Following outbreaks of foodborne illness that involved several cases of bloody diarrhea, E. coli O157:H7 was firmly associated with hemorrhagic colitis.

The Centers for Disease Control and Prevention (CDC) estimated in 1999 that 73,000 cases of E. coli O157:H7 occur each year in the United States. Approximately 2,000 people are hospitalized, and 60 people die as a direct result of E. coli O157:H7 infections and complications. The majority of infections are thought to be foodborne-related, although E.coli O157:H7 accounts for less than 1% of all foodborne illness.

E. coli O157:H7 bacteria are believed to mostly live in the intestines of cattle but have also been found in the intestines of chickens, deer, sheep, goats, and pigs. E. coli O157:H7 does not make the animals that carry it ill; the animals are merely the reservoir for the bacteria.

While the majority of foodborne illness outbreaks associated with E. coli O157:H7 have involved ground beef, such outbreaks have also involved unpasteurized apple and orange juice, unpasteurized milk, alfalfa sprouts, and water. An outbreak can also be caused by person-to-person transmission of the bacteria in homes and in settings like daycare centers, hospitals, and nursing homes.

Symptoms of an E. coli O157:H7 Infection

E. coli O157:H7 infection is characterized by the sudden onset of abdominal pain and severe cramps, followed within 24 hours by diarrhea. As the disease progresses, the diarrhea becomes watery and then may become grossly bloody – bloody to naked eye. Vomiting can also occur, but there is usually no fever. The incubation period for the disease (the period from ingestion of the bacteria to the start of symptoms) is typically 3 to 9 days, although shorter and longer periods are not that unusual. An incubation period of less than 24 hours would be unusual, however. In most infected individuals, the intestinal illness lasts about a week and resolves without any long-term problems.

Detection and treatment of E. coli O157:H7

Infection with E. coli O157:H7 is usually confirmed by detecting the bacteria in the stool of the infected individual. Antibiotics do not improve the illness, and some medical researchers believe that medications can increase the risk of complications. Therefore, apart from good supportive care, such as close attention to hydration and nutrition, there is no specific therapy for E. coli O157:H7 infection. The recent finding that a toxin produced by E. coli O157:H7 initially greatly speeds up blood coagulation may lead to medical therapies in the future that could forestall the most serious consequences. Most individuals recover within two weeks.

Preventing an E. coli O157:H7 Infection

Eating undercooked ground beef is the most important risk factor for acquiring E. coli O157:H7. Cook all ground beef and hamburger thoroughly. Because ground beef can turn brown before disease causing bacteria are killed, use a digital instant read meat thermometer to ensure thorough cooking. Hamburgers should be cooked until a thermometer inserted into several parts of the patty, including the thickest part, reads at least 160? F. Persons who cook ground beef without using a thermometer can decrease their risk of illness by not eating ground beef patties that are still pink in the middle. If you are served an undercooked hamburger or other ground beef product in a restaurant, send it back for further cooking.

Avoid spreading harmful bacteria in your kitchen. Keep raw meat separate from ready-to-eat foods. Wash hands, counters, and utensils with hot soapy water after they touch raw meat. Never place cooked hamburgers or ground beef on the unwashed plate that held raw patties. Wash meat thermometers in between tests of patties that require further cooking.

Drink only pasteurized milk, juice, or cider. Commercial juice with an extended shelf life that is sold at room temperature (such as juice in cardboard boxes or vacuum-sealed juice in glass containers) has been pasteurized, although this is generally not indicated on the label. Most juice concentrates are also heated sufficiently to kill pathogens.

Wash fruits and vegetables thoroughly, especially those that will not be cooked. Children younger than 5 years of age, immunocompromised persons, and the elderly should avoid eating alfalfa sprouts until their safety can be assured. Methods to decontaminate alfalfa seeds and sprouts are being investigated.

Drink municipal water that has been treated with chlorine or other effective disinfectants, or bottled water that has be sterilized with ozone or reverse osmosis (almost all major brands use one or the other method).

Avoid swallowing lake or pool water while swimming, especially pool water in public swimming facilities.

Avoid petting zoos and other animal exhibits unless there are good hand washing facilities available and other sanitation measures have been taken. Wash your hands and your children’s hands after handling animals.

Make sure that persons with diarrhea, especially children, wash their hands carefully with soap after bowel movements to reduce the risk of spreading infection, and that persons wash hands after changing soiled diapers. Anyone with a diarrheal illness should avoid swimming in public pools or lakes, sharing baths with others, and preparing food for others.

What is Hemolytic Uremic Syndrome?

Hemolytic Uremic Syndrome (HUS) is a severe, life-threatening complication of an E. coli O157:H7 bacterial infection. Although most people recover from an E. coli O157:H7 infection, about 5-10% of infected individuals goes on to develop HUS. E. coli O157:H7 is responsible for over 90% of the cases of HUS that develop in North America. Some organs appear more susceptible than others to the damage caused by these toxins, possibly due to the presence of increased numbers of toxin-receptors. These organs include the kidney, pancreas, and brain. Visit the Marler Clark sponsored Web site about Hemolytic Uremic Syndrome for more information.

What are the Symptoms associated with Hemolytic Uremic Syndrome?

About ten percent of individuals with E. coli O157:H7 infections (mostly young children) goes on to develop Hemolytic Uremic Syndrome, a severe, potentially life-threatening complication. HUS is an extremely complex process that researchers are still trying to fully explain.

Its three central features describe the essence of Hemolytic Uremic Syndrome: destruction of red blood cells (hemolytic anemia), destruction of platelets (those blood cells responsible for clotting, resulting in low platelet counts, or thrombocytopenia), and acute renal failure. In HUS, renal failure is caused when the nephrons, or filtering units, become occluded (blocked) by micro-thrombi, which are tiny blood clots. In almost all cases, the filtering ability of the kidneys recovers as the body of the patient slowly dissolves the micro-thrombi within the microvessels.

A typical person is born with about one million filtering units, called nephrons, in each kidney. The core of the nephron is a bundle of tiny blood vessels, called a glomerulus, where osmotic exchange allows for the filtration of wastes that eventually collect in the urine and are excreted. During Hemolytic Uremic Syndrome, the lack of blood flow to the nephrons can cause them to die or be damaged, just as heart muscle can die as the result of coronary vessel occlusion during a heart attack. Dead nephrons do not regenerate.

In general, the longer a patient suffers kidney failure, the greater the loss of filtering units as a result. At some point, the damage to the kidneys’ filtering units can be so severe that the patient will, over a period of years, lose kidney function and suffer end-stage renal disease (ESRD), which requires chronic dialysis or transplantation.

HUS can also cause transient or permanent damage to other organs, which include the pancreas, liver, brain, and heart. The essential pathogenic process is the same regardless of the organ affected: microthrombi inhibit necessary blood flow and cause tissue death or damage. During the acute stage of Hemolytic Uremic Syndrome, patients must be carefully monitored for these extra-renal complications. It is very difficult to predict the severity and course of HUS once it initiates.

The active stage of Hemolytic Uremic Syndrome may be defined as that period of time during which there is evidence of hemolysis and the platelet count is less than 100,000. In HUS, the active stage usually lasts an average of six days (range, 2-16 days). It is during the active stage that the complications of HUS per se usually occur.

For more information visit www.about-ecoli.com and www.about-hus.com.

Bill-color-headshotMarler Clark, The Food Safety Law Firm, is the nation’s leading law firm representing victims of E. coli outbreaks and hemolytic uremic syndrome (HUS). The E. coli lawyers of Marler Clark have represented thousands of victims of E. coli and other foodborne illness infections and have recovered over $600 million for clients. Marler Clark is the only law firm in the nation with a practice focused exclusively on foodborne illness litigation.  Our E. coli lawyers have litigated E. coli and HUS cases stemming from outbreaks traced to ground beef, raw milk, lettuce, spinach, sprouts, and other food products.  The law firm has brought E. coli lawsuits against such companies as Jack in the Box, Dole, ConAgra, Cargill, and Jimmy John’s.  We have proudly represented such victims as Brianne KinerStephanie Smith and Linda Rivera.


  1. Eisenstein, Barry and Zaleznik, Dori, “Enterobacteriiaceae,” in Mandell, Douglas, & Bennett’s PRINCIPLES AND PRACTICE OF INFECTIOUS DISEASES, Fifth Edition, Chap. 206, pp. 2294-2310 (2000).
  2. Feng, Peter, et al., “Enumeration of Escherichia coli and the Coliform Bacteria,” in BACTERIOLOGICAL ANALYTICAL MANUAL (8th Ed. 2002), available online at http://www.fda.gov/Food/FoodScienceResearch/LaboratoryMethods/BacteriologicalAnalyticalManualBAM/ucm064948.htm
  3. James M. Jay, MODERN FOOD MICROBIOLOGY at 21 (6th ed. 2000).
  4. Griffin, Patricia and Tauxe, Robert, “The Epidemiology of Infections Caused by Escherichia coli O157:H7, Other Enterohemorrhagic E. coli, and the Associated Hemolytic Uremic Syndrome,” EPIDEMIOLOGICAL REVIEW, Vol. 13, pp. 60-98 (1991).
  5. Frenzen, Paul D., et al., “Economic Cost of Illness due to Escherichia coli O157 Infections in the United States,” JOURNAL OF FOOD PROTECTION, Vol. 68, pp. 2623-2630 (2005).
  6. Bell, B.P., et al., “A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers:  the Washington experience.” JOURNAL OF AMERICAN MEDICAL ASSOCIATION, Vol. 272, pp. 1349-1353 (1994).
  7. Bala Swaminathan, et al., “PulseNet: Molecular Subtyping Network for Foodborne Bacterial Disease Surveillance, United States,” EMERGING INFECTIOUS DISEASES Vol. 7, No. 3, pp. 382-89 (May-June 2001).
  8. Konno T. et al., “Application of a multilocus variable number of tandem repeats analysis to regional outbreak surveillance of Enterohemorrhagic Escherichia coli O157:H7 infections,” JAPANESE JOURNAL OF INFECTIOUS DISEASE, Vol. 64, No. 1, pp. 63-5 (January 2011).
  9. Riley, LW, et al., “Hemorrhagic colitis associated with a rare Escherichia coli serotype,” NEW ENGLAND JOURNAL OF MEDICINE, Vol. 308, No. 12, pp. 681, 684-85 (1983).
  10. Feng, Peter, “Escherichia coli Serotype O157:H7: Novel Vehicles of Infection and Emergence of Phenotypic Variants,” EMERGING INFECTIOUS DISEASES, Vol. 1, No. 2, at 47 (April-June 1995).
  11. Keene, William E.,  et al., “A Swimming-Associated Outbreak of Hemorrhagic Colitis Caused by Escherichia coli O157:H7 and Shigella Sonnei,” NEW ENGLAND JOURNAL OF MEDICINE, Vol. 331, at 579 (Sept. 1, 1994).
  12. Ostroff, Stephen M., et al., “Infections with Escherichia coli O157:H7 in Washington State: The First Year of Statewide Disease Surveillance,” JOURNAL OF AMERICAN MEDICAL ASSOCIATION, Vol. 262, No. 3, at 355 (July 21, 1989).
  13. Rangel, Josefa M., et al., “Epidemiology of Escherichia coli O157:H7 Outbreaks, United States, 1982-2002,” EMERGING INFECTIOUS DISEASES, Vol. 11, No. 4, 603 (April 2005).
  14. Johannes, L, “Shiga toxins, from cell biology to biomedical applications,” NATIONAL REVIEW OF MICROBIOLOGY, Vol. 8, pp. 105-16 (2010).
  15. Suh, J.K., et al., “Shiga Toxin Attacks Bacterial Ribosomes as Effectively as Eucaryotic Ribosomes,” BIOCHEMISTRY, Vol. 37, No. 26, pp. 9394–398 (1998).
  16. Sandvig, K, “Pathways followed by ricin and Shiga toxin into cells,” HISTOCHEMISTRY AND CELL BIOLOGY, vol. 117, no. 2, pp. 131-141 (2002).
  17. Welinder-Olsson, C and Kaijser, B, “Enterohemorrhagic Escherichia coli (EHEC),” SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASE, Vol. 37, pp. 405-16 (2005).
  18. Kaper, J.B. and Karmali, M.A., “The Continuing Evolution of a Bacterial Pathogen,” PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, Vol. 105, No. 12, pp. 4535-4536 (March 2008).
  19. Wick, L.M., et al., “Evolution of genomic content in the stepwise emergence of Escherichia coli O157:H7,” JOURNAL OF BACTERIOLOGY, Vol. 187, pp. 1783–1791 (2005).
  20. Zhang, W, et al., “Probing genomic diversity and evolution of Escherichia coli O157 by single nucleotide polymorphisms,” GENOME RESEARCH, Vol. 16, pp. 757–67 (2006).  The full-text of this article is available online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1473186/pdf/757.pdf
  21. Robins-Browne, R.M., “The relentless evolution of pathogenic Escherichia coli,” CLINICAL INFECTIOUS DISEASES, Vol. 41, pp. 793–94 (2005).
  22. Manning S.D., et al., “Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaks,” PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, Vol. 105, No. 12, pp. 4868-73 (2008).
  23. Tauxe, Robert A., “Emerging Foodborne Diseases: An Evolving Public Health Challenge,” EMERGING INFECTIOUS DISEASES, Vol. 3, No. 4, pp. 425-427 (Oct.-Dec. 1997).
  24. CDC, “Multistate Outbreak of Escherichia coli O157:H7 Infections Associated with Eating Ground Beef—United States, June-July 2002,” MORBIDITY AND MORTALITY WEEKLY REVIEW, Vol. 51, at 638 (2002) reprinted in JOURNAL OF AMERICAN MEDICAL ASSOCIATION, Vol. 288, No. 6, 690 (Aug. 14, 2002).
  25. Scallan, E, et al., “Foodborne illness acquired in the United States –major pathogens,” EMERGING INFECTIOUS DISEASES, Vol. 17, No. 1, (Jan. 2011), available at:  http://www.cdc.gov/EID/content/17/1/7.htm.
  26. Su, Chinyu Su &Brandt,  Lawrence “Escherichia coli O157:H7 Infection in Humans,” ANNALS OF INTERNAL MEDICINCE, Vol.123, Issue 9, pp. 698-707 (1995).
  27. Juneja, V.K., et al., “Thermal Destruction of Escherichia coli O157:H7 in Hamburger,” JOURNAL OF FOOD PROTECTION, Vol. 60, No. 10, pp. 1163-1166 (1997).
  28. Griffin, Patricia M.,  et al., “Large Outbreak of Escherichia coli O157:H7 Infections in the Western United States: The Big Picture,” in RECENT ADVANCES IN VEROCYTOTOXIN-PRODUCING ESCHERICHIA COLI INFECTIONS, at 7 (M.A. Karmali & A. G. Goglio eds. 1994).
  29. Boyce, T.G., et al., “Escherichia coli O157:H7 and the hemolytic-uremic syndrome,” NEW ENGLAND JOURNAL OF MEDICINE, Vol. 333, pp. 364-368 (1995).
  30. Breuer, T, et al., “A multistate outbreak of Escherichia coli O157:H7 infections linked to alfalfa sprouts grown from contaminated seeds,” EMERGING INFECTIOUS DISEASES, Vol. 7, pp. 977-982 (2001).
  31. Friedman, M.S., et al., “Escherichia coli O157:H7 Outbreak Associated with an Improperly Chlorinated Swimming Pool,”  CLINICAL INFECTIOUS DISEASE, Vol. 29, No. 2, pp. 298-303 (1999).
  32. Cody, S.H., et al., “An outbreak of Escherichia coli O157:H7 infection from unpasteurized commercial apple juice,”  ANNALS OF INTERNAL MEDICINE, Vol. 130, No. 3, pp. 202-9 (1999).
  33. Siegler, Richard, “The Hemolytic Uremic Syndrome,” PEDIATRIC NEPHROLOGY, Vol. 42, p. 1505 (Dec. 1995)
  34. Chandler, W.L., et al., “Prothrombotic Coagulation Abnormalities Preceding the Hemolytic-Uremic Syndrome,” NEW ENGLAND JOURNAL OF MEDICINE, Vol. 346, No. 1, pp. 23-32 (2002).
  35. Elder, R.O., et al., “Correlation of enterohemorrhagic Escherichia coli O157 prevalence in feces, hides, and carcasses of beef cattle during processing,” USDA Agricultural Research Service, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (2000). http://www.pnas.org/content/97/7/2999.long
  36. Keen, J.E., et al., “Shiga-toxigenic Escherichia coli O157 in agricultural fair livestock, United States,” EMERGING INFECTIOUS DISEASES, Vol. 12, No. 5, pp. 780-86 (2003).
  37. King, L.J., Testimony on CDC Food Safety Activities and the Recent E. coli Spinach Outbreak, Hearing Before the Committee on Health, Education, Labor and Pensions, United States Senate,  Nov. 15, 2006, available online at http://www.hhs.gov/asl/testify/t061115.html.
  38. McCarthy, T.A., et al., “Hemolytic-Uremic Syndrome and Escherichia coli O121 at a Lake in Connecticut, 1999,” PEDIATRICS, vol. 108, pp. e59-59 (2001).
  39. Mead, Paul M., et al., “Food-related Illness and Death in the United States,”  EMERGING INFECTIOUS DISEASES, Vol. 5, pp. 607-625 (1999).
  40. Olsen, S.J., et al., “A Waterborne Outbreak of Escherichia coli O157:H7 Infections and Hemolytic Uremic Syndrome: Implications for Rural Water Systems,”  MORBIDITY AND MORTALITY WEEKLY REVIEW, Vol. 8, No. 4 (April 2002). The full text of article is available online at http://www.cdc.gov/ncidod/EID/vol8no4/00-0218.htm.
  41. Slutsker, L, et al., “A nationwide case-control study of Escherichia coli O157:H7 infection in the United States,” JOURNAL OF INFECTIOUS DISEASE, Vol. 177, pp. 962-966 (1998).
  42. Tarr, Philip, “Escherichia coli O157:H7:  Clinical, Diagnostic, and Epidemiological Aspects of Human Infection,”  CLINICAL INFECTIOUS DISEASE, Vol. 20, pp. 1-10 (1995).
  43. Wong, C.S., et al., “The risk of the hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections,” NEW ENGLAND JOURNAL OF MEDICINE, Vol. 342, pp.1930-36 (2000).
  44. Safdar, Nasia, et al., “Risk of Hemolytic Uremic Syndrome After Treatment of Escherichia coli O157:H7 Enteritis: A Meta-analysis,” JOURNAL OF AMERICAN MEDICAL ASSOCIATION, Vol. 288, No. 8, pp. 996 (Aug. 28, 2002).
  45. Garg, Amit X, et al., “Long-term Renal Prognosis of Diarrhea-Associated Hemolytic Uremic Syndrome: A Systematic Review, Meta-Analysis, and Meta-regression,” JOURNAL OF AMERICAN MEDICAL ASSOCIATION, Vol. 290, No. 10, p. 1360 (Sept. 10, 2003).
  46. Siegler, Richard, “Postdiarrheal Shiga Toxin-Mediated Hemolytic Uremic Syndrome,” JOURNAL OF AMERICAN MEDICAL ASSOCIATION, Vol. No. 10, p. 1379 (Sept. 10, 2003).
  47. Robitaille, Pierre, et al., “Pancreatic Injury in the Hemolytic Uremic Syndrome,” PEDIATRIC NEPHROLOGY, Vol. 11, pp. 631-32 (1997).
  48. Bell, Beth, et al., “Predictors of Hemolytic Uremic Syndrome in Children During a Large Outbreak of Escherichia coli O157:H7 Infections,” PEDIATRICS, Vol. 100, No. 1, p. 1 (July 1, 1997), full text available online at http://www.pediatrics.org/cgi/content/full/100/1/e12
  49. Marshall, J., et al., “Incidence and Epidemiology of Irritable Bowel Syndrome After a Large Waterborne Outbreak of Bacterial Dysentery,” GASTROENTEROLOGY, Vol. 131, pp. 445-50 (2006).
  50. Hungin, A., et al., “Irritable Bowel Syndrome in the United States: Prevalence, Symptom Patterns and Impact,” ALIMENTARY PHARMACOLOGY AND THERAPEUTICS, Vol. 21, No. 11, pp. 1365-75, (2005). Online at http://www.ncbi.nlm.nih.gov/pubmed/15932367
  51. Pollock, KG, et al., “Emotional and behavioral changes in parents of children affected by hemolytic-uremic syndrome associated with verocytotoxin-producing Escherichia coli: a qualitative analysis,” PYSCHOSOMATICS, Vol. 50, No. 3, pp. 263-9 (May-June 2009).
  52. Boxrud, D., “Genetic Testing,” Food Safety News, August 31, 2006, online at http://www.foodsafetynews.com/2009/08/genetic-testing-1/
  53. Boxrud D, et al., “Comparison of multiple-locus variable-number tandem repeat analysis, pulsed-field gel electrophoresis, and phage typing for subtype analysis of Salmonella enterica serotype Enteritidis,” JOURNAL OF CLINICAL MICROBIOLOGY, Vol. 45, No. 2, pp. 536-43 (Feb. 2007).
  54. CDC, “Recommendations for Diagnosis of Shiga Toxin–Producing Escherichia coli Infections by Clinical Laboratories,” MORBIDITY AND MORTALITY WEEKLY REVIEW, Vol. 88, No. RR-12 (Oct. 16, 2009), available online at http://www.cdc.gov/mmwr/PDF/rr/rr5812.pdf
  55. CDC, “Shiga toxin-producing Escherichia coli:  burden and trends.” FOODNET NEWS, Winter 2008. Available at: http://www.cdc.gov/FoodNet/news/2008/January_FoodNet_News.pdf
  56. Brooks, J. T., E. G. Sowers, J. G. Wells, K. D. Greene, P. M. Griffin, R. M. Hoekstra, and N. A. Strockbine.,“Non-O157 Shiga Toxin-Producing Escherichia coli Infections in the United States, 1983-2002.” J. INFECT DIS. 192:1422-9 (2005) available online at https://www.foodpoisonjournal.com/uploads/file/466536_web%5B1%5D.pdf
  57. Johnson, K. E., C. M. Thorpe, and C. L. Sears. “The Emerging Clinical Importance of Non-O157 Shiga Toxin-Producing Escherichia coli” CLIN INFECT DIS. 43:1587-95 (2006) available online at http://cid.oxfordjournals.org/content/43/12/1587.full.pdf+html
  58. Hussein, H. S. “Prevalence and pathogenicity of shiga toxin-producing Escherichia coli in beef cattle and their products.” J ANIM SCI. 85:E63-72 (2007) available online at http://jas.fass.org/content/85/13_suppl/E63.full.pdf
  59. Hussein, H. S. and T. Sakuma, “Prevalence of shiga toxin-producing Escherichia coli in dairy cattle and their products.” J DAIRY SCI. 88:450-65 (2005) abstract available online at http://www.ncbi.nlm.nih.gov/pubmed/15653509
  60. Fratamico, P.  “Non-O157 Shiga Toxin-Producing E. coli Associated with Muscle Foods. Meeting abstract.”  P.195.02.  (2007) available online at http://www.ars.usda.gov/research/publications/publications.htm?seq_no_115=210878
  61. Barkocy-Gallagher, G. A., T. M. Arthur, M. Rivera-Betancourt, X. Nou, S. D. Shackelford, T. L. Wheeler, and M. Koohmaraie. “Seasonal prevalence of Shiga toxin-producing Escherichia coli, including O157:H7 and non-O157:H7 serotypes, and Salmonella in commercial beef processing plants.”  J FOOD PROT. 66:1978-86 (2003) available online at http://www.ars.usda.gov/SP2UserFiles/Place/54380530/2003661978.pdf
  62. Hussein, H. S. and L. M. Bollinger. “Prevalence of Shiga toxin-producing Escherichia coli in beef.”  MEAT SCI. 71:676-89 (2005) available for purchase online at http://www.sciencedirect.com/science/article/pii/S0309174005002032
  63. Samadpour, M., V. Beskhlebnaya, and W. Marler. “Prevalence of non-O157 enterohaemmorrhagic Escherichia coli in retail ground beef in the United States.” 7th International Symposium on Shiga Toxin (Verocytoxin)-producing Escherichia coli Infections. Buenos Aires, Argentina. (2009) available at http://www.marlerblog.com/uploads/file/PREVALENCE%20OF%20NON.pdf
  64. Bosilevac J. M., M. N. Guerini, D. M. Brichta-Harhay, T. M. Arthur, and M. Koohmaraie. “Microbiological characterization of imported and domestic boneless beef trim used for ground beef.” J FOOD PROT. 70:440-9 (2007) available online at http://www.ars.usda.gov/SP2UserFiles/Place/54380530/2007700440.pdf
  65. Rasko, D.A. et al. “Origins of the E. coli Strain Causing an Outbreak of Hemolytic-Uremic Syndrome in Germany.”  N ENGL J MED 365:709-717 (2011) available online at http://www.nejm.org/doi/full/10.1056/NEJMoa1106920
  66. Wong, C.S. et al.  “Risk Factors for the Hemolyic Uremic Syndrome in Children Infected with Escherichia coli O157:H7:  a Multivariable Analysis”.  CLIN INFECT DIS first published online March 19, 2012 doi:10.1093/cid/cis299 available for purchase online at http://cid.oxfordjournals.org/content/early/2012/03/16/cid.cis299.full.pdf+html